The LENT score is a prognostic scoring system used for patients with malignant pleural effusion (MPE). The acronym LENT stands for four parameters: LDH (Lactate Dehydrogenase), ECOG performance status (Eastern Cooperative Oncology Group), Neutrophil-to-lymphocyte ratio (NLR), and Tumor type. 

This calculator is specifically applicable to patients diagnosed with malignant pleural effusion, a condition characterized by the abnormal accumulation of fluid in the pleural space due to malignancy. 

The clinical utility of the LENT score lies in its ability to predict survival in patients with MPE. It helps clinicians to stratify patients into different risk groups (low, moderate, and high) based on their LENT score, which can guide treatment decisions and discussions about prognosis with patients and their families.

There are no specific exclusion criteria for the use of the LENT score. However, it may not be as accurate in patients with rare types of cancer or in those with incomplete clinical data.

LENT score for malignant pleural effusion

# Description:
The LENT score is a prognostic scoring system used for patients with malignant pleural effusion (MPE). The acronym LENT stands for four parameters: LDH (Lactate Dehydrogenase), ECOG performance status (Eastern Cooperative Oncology Group), Neutrophil-to-lymphocyte ratio (NLR), and Tumor type. 

This calculator is specifically applicable to patients diagnosed with malignant pleural effusion, a condition characterized by the abnormal accumulation of fluid in the pleural space due to malignancy. 

The clinical utility of the LENT score lies in its ability to predict survival in patients with MPE. It helps clinicians to stratify patients into different risk groups (low, moderate, and high) based on their LENT score, which can guide treatment decisions and discussions about prognosis with patients and their families.

There are no specific exclusion criteria for the use of the LENT score. However, it may not be as accurate in patients with rare types of cancer or in those with incomplete clinical data.
---
# Inputs:
## LDH in pleural fluid, U/L
A. < 1,500 (+0)
B. >= 1,500 (+1)

## Eastern Cooperative Oncology Group performance score
C. 0 (asymptomatic) (+0)
D. 1 (symptomatic but ambulatory) (+1)
E. 2 (symptomatic, in bed < 50% of day) (+2)
F. 3-4 (symptomatic, in bed > 50% of day or bedbound) (+3)

## Serum neutrophil-to-lymphocyte ratio
G. < 9 (+0)
H. >= 9 (+1)

## Tumor type
I. Mesothelioma or hematologic malignancy (+0)
J. Breast or gynecologic cancer or renal cell carcinoma (+1)
K. Lung or any other cancer (+2)
---
# Scoring:
- If score <= 1, then Low risk group. Median survival is 319 days.
- If score <= 4, then Moderate risk group. Median survival is 130 days.
- If score >= 5, then High risk group. Median survival is 44 days.
- If score == 0, then Please make a selection)